Gallo, Daniela
De Vito, Annarosaria
Roncoroni, Rossella
Bruno, Antonino
Piantanida, Eliana
Bartalena, Luigi
Tanda, Maria Laura
Mortara, Lorenzo
Acquati, Francesco
Funding for this research was provided by:
Fondo di Ateneo per la Ricerca FAR 2020
Ministero dell’Istruzione, dell’Università e della Ricerca (2017NTK4HY)
Associazione Italiana per la Ricerca sul Cancro (AIRC-MFAG id 22818)
Fondazione Cariplo (id 2019-1609)
Article History
Received: 1 April 2022
Accepted: 20 September 2022
First Online: 30 September 2022
Compliance with ethical standards
:
: The authors declare no competing interests.
: This study was performed in line with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. This was a longitudinal observational study. According to the available guideline, patients were treated as per clinical practice with standard anti-thyroid drug treatment and the results on RNASET2 levels did not influence decisions on treatment. The research was included in studies on innate immunity in GD patients approved by the local ethical Committee (ASST dei Sette Laghi, Varese). All data were anonymized.
: Written informed consent was obtained from all individual participants included in the study.